MarkBHamnerMD

Geriatrics • Charleston, SC

Professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina College of Medicine

Join to view full profile

Dr. Hamner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hamner's full profile

Already have an account?

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Fax+1 843-937-6110

Education & Training

University of North Carolina HospitalsResidency, Psychiatry, 1982 - 1986
University of North Carolina at Chapel Hill School of MedicineClass of 1982

Certifications & Licensure

SC State Medical License 1991 - 2025
GA State Medical License 1986 - 2009
NC State Medical License 1985 - 1999
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Geriatric Psychiatry

Clinical Trials

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD) Start of enrollment: 2003 Aug 01
Completed
Phase 4
Quetiapine Augmentation for Treatment-resistant PTSD Start of enrollment: 2006 Jan 01
Completed
Phase 4
Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD) Start of enrollment: 2008 Jun 01
Withdrawn
Phase 2

Publications & Presentations

PubMed

A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder.
Michael A Norred, Zachary D Zuschlag, Mark B Hamner
Drugs. 2024-02-01
63 citations
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized ...
David W Oslin, Kevin G Lynch, Mei-Chiung Shih, Erin P Ingram, Laura O Wray
JAMA. 2022-07-12
10 citations
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
Olga Brawman-Mintzer, X. Charlene Tang, Marcel Bizien, Philip D. Harvey, Michael David Horner
Journal of Neurotrauma. 2021-07-01

Press Mentions

Exploring Psychopharmacology for PTSD & More Latest News HereAugust 14th, 2022